{
    "title": "Axovant to pull plug on Alzheimer's drug after key study fails",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-4921088/Axovants-Alzheimers-drug-fails-late-stage-trial-shares-slump.html",
    "date": "2017-09-26",
    "keywords": [
        "drug",
        "latestage",
        "dementia",
        "trial",
        "intepirdine",
        "divya",
        "grover",
        "disease",
        "companys",
        "percent",
        "receptor",
        "failure",
        "slew",
        "skorney",
        "protein",
        "year",
        "company",
        "developer",
        "axovant",
        "ltd",
        "memoryrobbing",
        "record",
        "low",
        "morning",
        "trading",
        "class",
        "antagonist",
        "neurotransmitter",
        "cognition",
        "potential",
        "treatment",
        "form",
        "lundbeck",
        "nail",
        "coffin",
        "mechanism",
        "analyst",
        "client",
        "note",
        "death",
        "blow",
        "hypothesis",
        "path",
        "cause",
        "biogen",
        "inc",
        "promis",
        "genentech",
        "blood",
        "brain",
        "aducanumab",
        "genentechs",
        "crenezumab",
        "therapy",
        "conference",
        "call",
        "focus",
        "gait",
        "balance",
        "midstage",
        "yearend",
        "population",
        "life",
        "expectancy",
        "improvement",
        "ability",
        "difference",
        "living",
        "placebo",
        "background",
        "value",
        "reporting",
        "mishra",
        "bengaluru",
        "editing",
        "sriraj",
        "kalluvila"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}